Lamotrigine
ID: SPE2D2-25-R-0002Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/f24e4e0ae1a8435e949b0b0233c215ab/view
Timeline
    Description

    The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Lamotrigine ER Tablets, specifically in dosages of 25MG, 50MG, 100MG, 200MG, 250MG, and 300MG, packaged in 30 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for various Department of Defense and other federal health service customers, including the Bureau of Prisons and the Department of Veterans Affairs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be fully competitive and unrestricted. Interested parties should prepare for the solicitation, projected for November 2024, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or by phone at 215-737-4955.

    Point(s) of Contact
    Nancy Fernandez
    (215) 737-4955
    nancy.fernandez@dla.mil
    Jason C. Wray
    (215) 737-0614
    Jason.Wray@dla.mil
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Lamotrigine
    Currently viewing
    Presolicitation
    Similar Opportunities
    6505--Lamotrigine Immediate Release (IR) Tablets
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Lamotrigine Immediate Release (IR) Tablets, aimed at ensuring a reliable supply for various federal health care facilities, including the Department of Defense and the Bureau of Prisons. The contract will cover an unrestricted procurement for multiple strengths and packaging sizes of Lamotrigine IR Tablets, with specific requirements for labeling and packaging to ensure compliance with safety standards. This procurement is critical for maintaining the availability of essential medications for veterans and other federal beneficiaries. Interested offerors should note that the solicitation is expected to be released on or about November 7, 2024, with a closing date of November 21, 2024; inquiries can be directed to Contract Specialist Ray Roldan at raymond.roldan@va.gov or by phone at 708-786-4930.
    Dimethyl Fumarate DR Presolicitation
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Bicalutamide 50MG tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Bicalutamide 50MG tablets, available in bottle counts of 30 and 500. The procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for various Department of Defense and other federal health programs. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base period and four one-year options, with the solicitation expected to be posted on the DLA Bid Board System and Sam.gov. Interested parties should direct inquiries to Keith Ryales at keith.ryales@dla.mil or call 215-737-9199 for further information.
    Norgestimate/Ethinyl Estradiol Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a presolicitation for a national requirements contract for Norgestimate/Ethinyl Estradiol Tablets. The procurement will include various formulations of these oral tablets, specifically Norgestimate Ethinyl Estradiol Triphasic Low Dose Oral Tablets and Ethinyl Estradiol/Norgestimate tablets, packaged in 3x28 count packs. This contract is crucial for establishing a national supply source for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons, ensuring a reliable provision of these essential pharmaceuticals. Interested parties should prepare for the solicitation, projected for November 2024, and may contact Kyle Lewicki at (215) 737-3696 or kyle.lewicki@dla.mil for further inquiries.
    Potassium Chloride Extended Release Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting bids for the procurement of Potassium Chloride Extended Release Tablets under Solicitation No. SPE2D2-24-R-0013. This procurement involves various package sizes of potassium chloride tablets, specifically 10 MEQ and 20 MEQ in both 100 and 500 count bottles, with estimated quantities spanning a base year and four optional additional years. The initiative is crucial for maintaining a reliable supply of essential pharmaceuticals to support healthcare needs within the Department of Defense. Interested suppliers must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by the deadline of October 10, 2024. For further inquiries, potential bidders can contact Ryan Guarnere at ryan.guarnere@dla.mil or Jason Wray at jason.wray@dla.mil.
    Pramipexole Tablets
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for Pramipexole Tablets under solicitation number SPE2D2-24-R-0017. This procurement aims to acquire pharmaceutical products, specifically Pramipexole in various dosages, to support military health needs. The solicitation outlines detailed requirements for offerors, including submission instructions via the Defense Logistics Agency Internet Bid Board System (DIBBS), compliance with federal regulations, and the necessity for performance assessments and ethical conduct. Interested contractors should reach out to Ryan Guarnere at Ryan.Guarnere@dla.mil or Jason Wray at jason.wray@dla.mil for further information regarding the submission process and compliance requirements.
    Metformin HCL
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Pantoprazole DR Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Rizatriptan Benzoate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
    Rabeprazole Sodium Delayed Release Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.